Four year data from Phase III CHECKMATE 067 trial shows durable long term survival results with Opdivo + Yervoy- BMS

Bristol-Myers Squibb Company announced four-year data from the Phase III CheckMate -067 clinical trial � the longest follow-up to date � which continues to demonstrate durable, long-term survival benefits with the first-line combination of Opdivo (nivolumab) and Yervoy (ipilimumab), versus Yervoy alone, in patients with advanced melanoma. With a minimum follow-up of 48 months, four-year overall survival rates were 53% for the Opdivo plus Yervoy combination, 46% for Opdivo alone, and 30% for Yervoy alone. Additionally, the percentage of patients experiencing a complete response have continued to increase with complete response rates of 21% for Opdivo plus Yervoy, 18% for Opdivo alone, and 5% for Yervoy alone. In addition, results of an analysis of patients who were alive at the time of the four-year analysis showed that a higher proportion of patients were treatment-free (i.e., off study treatment and free of systemic subsequent therapy) in the combination group (71%) compared with the monotherapy groups (50% for Opdivo and 39% for Yervoy). The safety profile for Opdivo plus Yervoy in CheckMate -067 at four years was consistent with prior findings, with no new safety signals and no additional treatment-related deaths. Data from CheckMate -067 (Presentation #LBA44) will be featured in an oral presentation at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany, October 19-23, with simultaneous publication in The Lancet Oncology.

See- "Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial"-Frank Stephen Hodi, MD Vanna Chiarion-Sileni, MD Prof Rene Gonzalez, MD. et al. Published:October 22, 2018DOI:https://doi.org/10.1016/S1470-2045(18)30700-9.